No abstract

No abstract

Introduction Pericardial hydatid cyst comprises 7% of all cardiac hydatidosis, but its occurrence is concomitant with several life-threatening complications. This study is a review of the reported studies of pericardial hydatid cysts. Methods A systematic review of the published studies of pericardial hydatid cysts was conducted. The studies of cardiac hydatid cysts with the following properties were included: 1) The pericardium infection was confirmed by diagnostic modalities, surgical findings, or histopathology. 2) The case presentation was provided in the study. 3) The cyst (s) originally located or adhered to the pericardium and did not rupture into it from the other adjacent cardiac structures or organs. Results Overall, 106 studies were compatible with the inclusion criteria. Most of the cases (29.72%) were reported in Turkey, followed by India (18.24%). There was no gender predilection, and the age of the patients was distributed between 5 and 80 years old. The most common symptoms were chest pain (43%), and dyspnea (36%). Hydatid cysts were only found in the pericardium in 56% of cases and multiloculated in 44%. Surgery was the treatment of choice (87.8%), and cystectomy (72.3%) was the major technique of cyst removal. The total number of recurrences was 3 cases (2%). There was a significant correlation between recurrence and the history of hydatidosis. The mortality rate was 2.7%. Conclusion Pericardial hydatid disease is more common in subtropical regions. The definitive treatment of a pericardial hydatid cyst is surgery, mainly through a median sternotomy. A history of hydatidosis increases the likelihood of recurrence.

No abstract

Introduction Pericardial effusion (PE) related to COVID-19 has rarely been observed, with most reported cases being non-hemorrhagic. This study aims to present a rare case of post-COVID-19 hemorrhagic PE. Case report A 44-year-old male presented with shortness of breath upon exertion, palpitation, and left-sided chest tightness. He was a recently recovered from COVID-19. He was conscious, oriented, tachypneic, and tachycardic. Chest examination revealed a mixture of fine and coarse crackles along with muffled heart sounds. He had elevated D-dimer, C-reactive protein, prothrombin time, and aPTT. Computed tomography pulmonary angiogram showed acute pulmonary thromboembolism involving the posterior segmental lobar branch of the left lower lobe with concomitant pulmonary infarction. Echocardiography showed severe PE without diastolic collapse. Pericardial drainage was performed and by the 2nd day, there was no more effusion. On the 7th day, the patient developed severe complications which led to cardiac arrest. Discussion PE is the buildup of fluid in the pericardium. It has been rarely observed in relation to COVID-19, both during and after the viral infection. If PE is suspected, Echocardiography can be used to confirm its diagnosis. There is no standard management for these cases and only non-hemorrhagic patients with mild to moderate effusion can be treated using conservative measures. Conclusion Hemorrhagic PE can be a rare but possible post-COVID-19 sequel, and Echo can be used to confirm its diagnosis. Drainage is necessary to resolve the effusion.